RainDance Launches ThunderBolts Next-Gen Sequencing Cancer Panel
This article was originally published in The Gray Sheet
RainDance Technologies announced the official launch of the ThunderBolts cancer panel this week at the American Association for Cancer Research annual meeting in San Diego, where researchers demonstrated the system’s ability to genetically profile various types of tumors for as little as $100 per sample.
You may also be interested in...
Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.
SyncThink recently obtained a CE mark for the Eye-Sync system, using the PicoXR Neo 3 Pro Eye virtual-reality headset, to measure and quantify eye-movement biomarkers reflective of neurological impairment or disease.